ArticleBMC medicine2025
Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of micro-particulate allografts is rising, but knowledge about the protein characterization and biocompatibility of umbilical cord-derived allografts (UC) in vivo is limited.
methodsProteomic analyses using mass spectrometry (MS) determined equine UC protein relative quantification and functions using total spectral counts (TSC). UC cytokines were quantified by enzyme-linked immunosorbent assay (ELISA). Three in vivo studies assessed recipient clinical and tissue biocompatibility in joints and ligaments.
resultsProteomics revealed 2645 annotated TSCs. Proteins of > 89 TSC were considered abundant and were present in all donors. Proteins within the same donor had a 4.7% mean variation. Inflammatory cytokines were low in UC. In vivo, the prospective randomized, masked, controlled study in carpal joints and ligaments of clinically normal horses had median scores of 0 (none) for lameness and pain for 42 days. Synovial fluid showed a transient transudative synovitis after UC injection that was greater than baseline and control and returned to normal after day 5 (P < 0.001). Synovial fluid inflammatory cytokines were low; however, the anti-inflammatory cytokines Il-1ra, Il-10, and Il-1ra/Il-1 ratio were greater after UC injection than at baseline and control (P < 0.001). Blood hematology, chemistries, and serum amyloid A did not reveal systemic effects. The in vivo study of osteoarthritis and desmitis/tendonitis improved in lameness and pain over a 28-day study and had parallel synovial fluid results to the normal horse study, also without adverse events. The in vivo pathologic study evaluated joint and ligament tissues 2 and 5 days after injection and corresponding lymph nodes for evidence of the allograft or inflammation. The synovial membrane, articular cartilage, and lymph nodes were histologically normal, except for mild inflammation in the injection tracts.
conclusionsWell-defined proteins were consistently present in different donors and within batches. Proteins included fibrillar and glycan proteins with a variety of roles and regulatory functions in the connective tissue matrix. The rise in Il-1ra and high Il-1ra/Il-1 ratio after UC injection could block the catabolic effect of Il-1. No adverse events were observed. Within the limits of this study, UC was safe for injection into joints and ligaments in clinically normal horses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.